Gilead Sciences

Biotechnology

GILD

$ 63 1.4

Share price

$ 79 bn

Market Cap

$ 102 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.03x the weighted average for S&P 500

FY2020

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

In line with the -5.1% weighted average for S&P 500

FY2021

Gilead Sciences aims to reduce Scope 1 + 2 by 46% by 2030 from a base year 2019

1.5°C

Secondary Climate Goal

Gilead Sciences aims to reduce Scope 3 by 15% by 2030 from a base year 2019

1.5°C

GHG emissions and Carbon intensity

Gilead Sciences reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 84 Kt (+12/+16% y-o-y). Carbon intensity also was up at 3.4 t (+0.2/+6.2% y-o-y).

Gilead Sciences's Scope 3 emissions surged to 38 Kt (+5.1/+16% y-o-y). The growth accelerated relative to the long-term trend (+6.1% CAGR) observed since 4Q'16.

The company is committed to reducing Scope 1 + 2 by 46% by 2030 from a base year 2019, which translates into the estimated reduction of -4.5 Kt per annum over the period of FY2021 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2020Q4	84	48	36		24,689	3.4
2019Q4	73	52	21		22,449	3.2
2018Q4	72	47	26	38	22,127	3.3
2017Q4	76	47	29	33	26,107	2.9
2016Q4	82	45	37	32	30,390	2.7